Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products - - BioPharm International

ADVERTISEMENT

Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products


Untitled Document

During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.

Presenter:
Jeri Ann Boose, Ph.D.
Director, Biopharmaceutical Services
Lancaster Laboratories

Katherine Bergmann, Ph.D.
Manager, Viral Safety and Viral Clearance Services
Lancaster Laboratories

Online Resources:
Register for the Live Web Conference
More Information

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here